Recent years have brought significant innovation in potentially curative therapies for several diseases. By 2025, the FDA anticipates approving 10 to 20 cell and gene therapy products per year, many of which are intended to be one-time curative treatments.
But despite these efforts to accelerate the evaluation of drug safety and efficacy, uptake of many new therapies has been much slower than expected. Why the lag? Great thoughts in the latest Harvard Business Review from Precision Xtract team members James Baumgardner, Rebecca Kee, Scientific Advisor Dr. Bapu Jena and others.
Read the full article here.
